8-K: Qualigen Therapeutics Changes Independent Auditor from Baker Tilly to WithumSmith+Brown

Qualigen Therapeutics has dismissed Baker Tilly US, LLP as its independent auditor and engaged WithumSmith+Brown, PC, effective July 11, 2024.

Summary

• Qualigen Therapeutics dismissed Baker Tilly US, LLP as their independent auditor on July 11, 2024.
• Baker Tilly had served as the company's auditor since 2018.
• The decision to change auditors was approved by the company's audit committee.
• The audit reports from Baker Tilly for the fiscal years ending December 31, 2023 and 2022 did not contain any adverse opinions or disclaimers, but included an explanatory paragraph about the company's ability to continue as a going concern.
• There were no disagreements with Baker Tilly on accounting principles, financial statement disclosure, or auditing scope.
• Baker Tilly did communicate a material weakness to the company's audit committee.
• Qualigen Therapeutics has engaged WithumSmith+Brown, PC as their new independent auditor, effective July 11, 2024.
• Withum will audit the company's financial statements for the year ending December 31, 2024.
• The company did not consult with Withum on any accounting or auditing matters prior to their engagement.

Sentiment

Score: 3

Explanation: The change in auditors, combined with the going concern note and material weakness, suggests potential financial instability and raises concerns about the company's future prospects.

Positives

• The transition to a new auditor was approved by the audit committee.
• There were no disagreements with the previous auditor on accounting principles or practices.
• The company has authorized both the former and new auditors to fully respond to inquiries from each other.

Negatives

• The previous auditor's reports included an explanatory paragraph about the company's ability to continue as a going concern.
• A material weakness was communicated by the previous auditor to the audit committee.

Risks

• The change in auditors could potentially raise concerns among investors.
• The material weakness identified by the previous auditor could indicate underlying financial or operational issues.
• The going concern note in the previous audit reports suggests potential financial instability.

Future Outlook

WithumSmith+Brown, PC will audit the company's financial statements for the year ending December 31, 2024.

Management Comments

• The decision to change the independent public accounting firm was approved by the audit committee of the Company's board of directors.

Industry Context

Changes in auditors are not uncommon, but they can sometimes signal underlying issues or a desire for a fresh perspective on financial reporting. The fact that the previous auditor raised concerns about the company's ability to continue as a going concern is a significant factor.

Comparison to Industry Standards

• It is common for companies to change auditors periodically, but the circumstances surrounding this change, including the going concern note and material weakness, are not typical.
• Many companies in the biotech sector, especially those with limited revenue, face going concern issues, but the communication of a material weakness is a more serious concern.
• Companies like Amgen, Gilead, and Regeneron, which are established biotech firms, typically do not have these types of auditor issues.

Stakeholder Impact

• Shareholders may be concerned about the change in auditors and the going concern note.
• Creditors may be more cautious about extending credit to the company.
• Employees may be concerned about the company's financial stability.

Next Steps

• WithumSmith+Brown, PC will conduct the audit for the fiscal year ending December 31, 2024.

Key Dates

Keywords

auditor, accounting, financial statements, Baker Tilly, WithumSmith+Brown, audit committee, material weakness, going concern